Q-omics provides the consensus-scored DUXAP9 profile across patient tissues and cancer cell-line models. DUXAP9 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DUXAP9 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DUXAP9 RNA expression shows 16,522 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where DUXAP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUXAP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUXAP9 survival associations across molecular data types. DUXAP9 RNA expression shows survival associations in the most cancer types (29). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUXAP9 RNA expression–survival associations across cancer types. High DUXAP9 expression shows unfavorable associations in KIRC, KIRP, ACC, LIHC, KICH and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DUXAP9 RNA expression.
This table summarizes DUXAP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DUXAP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUXAP9 shows higher tumor expression in HNSC, KIRC, KIRP, UCEC, LUSC and BLCA. The HNSC box plot shows higher DUXAP9 RNA expression in tumor versus normal tissue (log2 FC = +0.618, t-test p < 0.001).
This table shows molecular features associated with DUXAP9 in patient tissues and cancer cell lines. In patient samples, DUXAP9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
